Back to today’s briefing

Story perspectives

UK Approves First GLP-1 Tablet Foundayo for Obesity, Diabetes

8/10/2026

50 10 Full Breakdown

Summary

Story summary

The UK MHRA authorized orforglipron (Foundayo) on 10 August 2026, the first GLP-1 tablet for weight loss and type 2 diabetes.
Eli Lilly markets the tablet for adults with BMI >= 30 or BMI 27-30 with a weight-related condition and for uncontrolled type 2 diabetes.
Trials showed a year of use kept weight loss after stopping injectables, but nausea, constipation and abdominal pain were reported.
The drug awaits a NICE review before NHS adoption.

1 of 1

Story summary

The UK MHRA authorized orforglipron (Foundayo) on 10 August 2026, the first GLP-1 tablet for weight loss and type 2 diabetes.
Eli Lilly markets the tablet for adults with BMI >= 30 or BMI 27-30 with a weight-related condition and for uncontrolled type 2 diabetes.
Trials showed a year of use kept weight loss after stopping injectables, but nausea, constipation and abdominal pain were reported.
The drug awaits a NICE review before NHS adoption.